NASDAQ:NKTX

Nkarta Stock News

Healthcare > Biotechnology

Buy NKTX

*Your capital is at risk

$2.72

-0.190 (-6.53%)

At Close: Jun 03, 2026

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

04:02pm, Thursday, 13'th May 2021

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today r

Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer

11:38am, Friday, 07'th May 2021

Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split al

NKTX Stock: Over 10% Increase Pre-Market Explanation

06:40am, Friday, 07'th May 2021

The stock price of Nkarta Inc (NASDAQ: NKTX) increased by over 10% pre-market. This is why it happened.

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

08:02am, Wednesday, 28'th Apr 2021

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

04:03pm, Thursday, 25'th Mar 2021

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to trea

Biotech Shares Have Soared Since 2020's Wave of IPOs

09:45am, Wednesday, 17'th Feb 2021

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Nkarta Reports Third Quarter 2020 Financial Results

04:03pm, Thursday, 12'th Nov 2020

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat

Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101

04:02pm, Thursday, 12'th Nov 2020

First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D

Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer

08:02am, Monday, 09'th Nov 2020

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat

The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter

12:00am, Thursday, 30'th Jul 2020

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Adamis Pharmaceuticals Corp (NASDAQ: ADMP) Annexon...

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by